glp-1 weight regain after stopping Woman shares journey of loss and gain using semaglutide Stopping Weight-Loss Injections May Trigger

Phase 3 trial results (REDEFINE program) showed CagriSema produced approximately 22-25% body weight reduction, putting it in direct competition with tirzepatide and retatrutide

Mitochondrial BCL-2 inhibits AMBRA1-induced autophagy

Researchers report that GLP-1 drugs prescribed for weight loss may improve cognition and lower dementia and cardiovascular disease risk

Occipital cortex tCho levels in the occipital cortex showed a significant effect of aura status, although this did not survive correction for multiple comparisons (F(2,25.9) = 4.02, p = 0.03, p B = 0.09)

GSH as a targeting molecule was described to increase the adhesion force between living brain endothelial cell surface and GSH-modified nanostructures measured by optical tweezer method [64]

Important Safety Note: GLP-1 medications are generally contraindicated (not recommended) for anyone with a personal or family history of Medullary Thyroid Cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)